Compounded semaglutide vs Ozempic: cost, safety, and the rules

No. Ozempic is FDA-approved semaglutide, manufactured to strict standards and studied in large clinical trials. Compounded semaglutide is made by a compounding pharmacy, is not FDA-approved, and was never put through the FDA efficacy or safety review — there are no randomized trials of the compounded product. It may contain the same base molecule, but purity, dose accuracy, and formulation are not FDA-verified, and some compounders have used different salt forms (semaglutide sodium or acetate) that the FDA has flagged as not the same active ingredient. The FDA has logged hundreds of adverse-event reports tied to compounded semaglutide.

The situation changed. Widespread compounding was allowed while semaglutide was in official FDA shortage, but that shortage was declared resolved in February 2025, and the enforcement grace periods for pharmacies ended in 2025 (503A in April, 503B in May). In 2026 the FDA proposed further restricting bulk semaglutide compounding. So the era of freely available "essentially a copy" compounded semaglutide has largely ended. Compounding can still be legal in narrower situations — for example, a documented clinical need for a formulation a patient can't use off the shelf — but that is different from mass-market copies. Availability and legality now depend heavily on the specific pharmacy and your clinical situation.

A 503A pharmacy is a traditional state-licensed pharmacy that compounds a medication for an individual patient with a specific prescription; it is not required to follow full federal manufacturing (cGMP) standards and is not FDA-registered as a facility. A 503B is an FDA-registered outsourcing facility that can compound in larger batches, must follow cGMP quality standards, and is subject to FDA inspection. If you are considering any compounded product, a 503B facility generally carries stronger quality oversight — and knowing which type your source is is one of the most useful safety questions you can ask.

Compounded semaglutide has often been advertised around $69–$300/mo, versus Ozempic's list price of about $969–$998/mo. The gap exists because compounded products skip the FDA approval process, brand development, and manufacturing overhead — which is also exactly why they carry more uncertainty about purity, dosing, and consistency. Note that brand semaglutide's real out-of-pocket cost can be lower than the list price through manufacturer cash programs (Ozempic has an introductory self-pay near $199/mo), so compare the actual price you'd pay, not list vs compounded.

If cost pushes you toward compounded, reduce the risk: use a provider that dispenses through a reputable, ideally 503B, pharmacy; confirm the product is base semaglutide (not a "sodium" or "acetate" salt form); insist on clear dosing instructions; and be wary of anything sold without a prescription or a real clinician. The FDA-approved options (Ozempic, Wegovy) remain the only versions actually tested for safety and efficacy. This is a genuine trade-off to weigh with a licensed clinician — not a decision to make on price alone.

Almost never — and this is where the price comparison often inverts. A compounded program's cash price is the entire price permanently: there is no copay to fall back on and no appeal route if it rises. An approved product like Ozempic can drop to a copay if covered, and a denial can be appealed, with manufacturer cash and assistance programs as further fallbacks. Before choosing the compounded path on headline cost, find out what your plan would actually charge for the approved product.

Six things: which pharmacy dispenses it and where it is licensed; whether the product is base semaglutide rather than a salt form (get this in writing); what the dosing instructions are in both units and milligrams, since unit confusion is a documented source of dosing errors; what you pay all-in at your maintenance dose rather than the starting-dose headline; what the refund policy is if you stop, since discontinuation during titration is common; and who you contact clinically if something goes wrong — a named clinician, not a support inbox.